JPWO2020218465A1 - - Google Patents

Info

Publication number
JPWO2020218465A1
JPWO2020218465A1 JP2021516229A JP2021516229A JPWO2020218465A1 JP WO2020218465 A1 JPWO2020218465 A1 JP WO2020218465A1 JP 2021516229 A JP2021516229 A JP 2021516229A JP 2021516229 A JP2021516229 A JP 2021516229A JP WO2020218465 A1 JPWO2020218465 A1 JP WO2020218465A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021516229A
Other languages
Japanese (ja)
Other versions
JPWO2020218465A5 (https=
JP7535270B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020218465A1 publication Critical patent/JPWO2020218465A1/ja
Publication of JPWO2020218465A5 publication Critical patent/JPWO2020218465A5/ja
Priority to JP2024119174A priority Critical patent/JP2024150669A/ja
Application granted granted Critical
Publication of JP7535270B2 publication Critical patent/JP7535270B2/ja
Priority to JP2026010934A priority patent/JP2026065204A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021516229A 2019-04-26 2020-04-24 子宮内膜症の診断方法、病態モニタリング方法及びキット Active JP7535270B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024119174A JP2024150669A (ja) 2019-04-26 2024-07-25 子宮内膜症の診断方法、病態モニタリング方法及びキット
JP2026010934A JP2026065204A (ja) 2019-04-26 2026-01-27 子宮内膜症の診断方法、病態モニタリング方法及びキット

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019086223 2019-04-26
JP2019086223 2019-04-26
PCT/JP2020/017595 WO2020218465A1 (ja) 2019-04-26 2020-04-24 子宮内膜症の診断方法、病態モニタリング方法及びキット

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024119174A Division JP2024150669A (ja) 2019-04-26 2024-07-25 子宮内膜症の診断方法、病態モニタリング方法及びキット

Publications (3)

Publication Number Publication Date
JPWO2020218465A1 true JPWO2020218465A1 (https=) 2020-10-29
JPWO2020218465A5 JPWO2020218465A5 (https=) 2024-01-04
JP7535270B2 JP7535270B2 (ja) 2024-08-16

Family

ID=72942212

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021516229A Active JP7535270B2 (ja) 2019-04-26 2020-04-24 子宮内膜症の診断方法、病態モニタリング方法及びキット
JP2024119174A Pending JP2024150669A (ja) 2019-04-26 2024-07-25 子宮内膜症の診断方法、病態モニタリング方法及びキット
JP2026010934A Pending JP2026065204A (ja) 2019-04-26 2026-01-27 子宮内膜症の診断方法、病態モニタリング方法及びキット

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024119174A Pending JP2024150669A (ja) 2019-04-26 2024-07-25 子宮内膜症の診断方法、病態モニタリング方法及びキット
JP2026010934A Pending JP2026065204A (ja) 2019-04-26 2026-01-27 子宮内膜症の診断方法、病態モニタリング方法及びキット

Country Status (5)

Country Link
US (1) US20220221472A1 (https=)
EP (1) EP3961217A4 (https=)
JP (3) JP7535270B2 (https=)
CN (1) CN113994208A (https=)
WO (1) WO2020218465A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013783A1 (en) * 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a12 as blood biomarker for the non-invasive diagnosis of endometriosis
KR20220154725A (ko) * 2020-03-16 2022-11-22 프로테오믹스 인터내셔널 피티와이 리미티드 자궁내막증 바이오마커
CN113325183B (zh) * 2021-06-01 2022-11-15 中国医学科学院北京协和医院 一种用于鉴别诊断em/fem的试剂盒
WO2025026908A1 (en) * 2023-07-28 2025-02-06 Roche Diagnostics Gmbh Serum epha1 as biomarker for endometriosis
WO2025084848A1 (ko) * 2023-10-18 2025-04-24 주식회사 노브메타파마 Clic1을 이용한 섬유증 치료제의 스크리닝 방법
WO2025260122A1 (en) * 2024-06-19 2025-12-26 Proteomics International (Ip) Pty Ltd Biomarkers for endometriosis
GB202410764D0 (en) * 2024-07-23 2024-09-04 Univ Of Hull Diagnostic test
CN118995917A (zh) * 2024-09-30 2024-11-22 暨南大学 Ppif基因作为标志物在子宫内膜异位症诊断评估中的应用
CN121304682B (zh) * 2025-12-15 2026-03-31 西安市第一医院 基于图像处理的子宫内膜异位症病灶智能识别方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002325600A (ja) * 2000-09-25 2002-11-12 Schering Ag 子宮内膜症のインビトロ診断法
JP2003531580A (ja) * 2000-02-25 2003-10-28 メトリオジェーン・バイオサイエンシイズ・インコーポレイテッド 子宮内膜症関連マーカー及びその使用
JP2009168646A (ja) * 2008-01-17 2009-07-30 Fuji Pharmaceutical Co Ltd 子宮内膜症に特異的なバイオマーカー
US20090281110A1 (en) * 2006-06-23 2009-11-12 Jakob Busch-Petersen Method of Treatment
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
JP2013518606A (ja) * 2010-02-09 2013-05-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規使用
US20140274787A1 (en) * 2005-06-22 2014-09-18 Vermillion, Inc. Biomarker for ovarian cancer ctap3-related proteins
WO2015174544A1 (ja) * 2014-05-16 2015-11-19 国立研究開発法人国立精神・神経医療研究センター 精神疾患判定マーカー
US20160251718A1 (en) * 2013-10-01 2016-09-01 The Regents Of The University Of California Endometriosis Classifier

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374370T1 (de) * 1999-01-25 2007-10-15 Siemens Medical Solutions Diag Verfahren zur diagnose von endometriose
AU2003253440A1 (en) * 2002-08-30 2004-04-30 Japan As Represented By The President Of The University Of Tokyo Method of diagnosing ovarian endometriosis
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
WO2013178794A1 (en) * 2012-05-31 2013-12-05 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) A novel method for the diagnosis of endometriosis
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
KR20170014561A (ko) * 2015-07-30 2017-02-08 한국과학기술연구원 Ｃｘｃｌ7 측정 제제를 포함하는 대장암 진단용 조성물, 키트, 및 이를 이용한 대장암 진단 방법

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531580A (ja) * 2000-02-25 2003-10-28 メトリオジェーン・バイオサイエンシイズ・インコーポレイテッド 子宮内膜症関連マーカー及びその使用
JP2002325600A (ja) * 2000-09-25 2002-11-12 Schering Ag 子宮内膜症のインビトロ診断法
US20140274787A1 (en) * 2005-06-22 2014-09-18 Vermillion, Inc. Biomarker for ovarian cancer ctap3-related proteins
US20090281110A1 (en) * 2006-06-23 2009-11-12 Jakob Busch-Petersen Method of Treatment
JP2009168646A (ja) * 2008-01-17 2009-07-30 Fuji Pharmaceutical Co Ltd 子宮内膜症に特異的なバイオマーカー
JP2013518606A (ja) * 2010-02-09 2013-05-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規使用
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
US20160251718A1 (en) * 2013-10-01 2016-09-01 The Regents Of The University Of California Endometriosis Classifier
WO2015174544A1 (ja) * 2014-05-16 2015-11-19 国立研究開発法人国立精神・神経医療研究センター 精神疾患判定マーカー

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EK, MALIN ET AL.: "AXIN1 in Plasma or Serum Is a Potential New Biomarker for Endometriosis", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20(1), 189, JPN7020001329, 7 January 2019 (2019-01-07), pages 1 - 12, ISSN: 0005236021 *
FASSBENDER, AMELIE ET AL.: "Update on Biomarkers for the Detection of Endometriosis", BIOMED RESEARCH INTERNATIONAL, vol. Volume 2015, Article ID 130854, JPN7020001326, 2015, pages 1 - 14, ISSN: 0005236022 *
GRANDE, GIUSEPPE ET AL.: "Cervical mucus proteome in endometriosis", CLINICAL PROTEOMICS, vol. 14:7, JPN7020001328, 2 February 2017 (2017-02-02), pages 1 - 11, ISSN: 0005236024 *
IRUNGU, STELLA ET AL.: "Discovery of non-invasive biomarkers for the diagnosis of endometriosis", CLINICAL PROTEOMICS, vol. 16:14, JPN7020001327, 6 April 2019 (2019-04-06), pages 1 - 16, ISSN: 0005236023 *

Also Published As

Publication number Publication date
EP3961217A4 (en) 2023-09-27
JP2026065204A (ja) 2026-04-14
JP2024150669A (ja) 2024-10-23
CN113994208A (zh) 2022-01-28
JP7535270B2 (ja) 2024-08-16
EP3961217A1 (en) 2022-03-02
US20220221472A1 (en) 2022-07-14
WO2020218465A1 (ja) 2020-10-29

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240308

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240725

R150 Certificate of patent or registration of utility model

Ref document number: 7535270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150